Tenaya Therapeutics, Inc. expected to post a loss of 10 cents a share - Earnings Preview
Tenaya Therapeutics, Inc. TNYA.O is expected to show a rise in quarterly revenue when it reports results for the period ending December 31 2026
The South San Francisco California-based company is expected to report revenue of $2.618 million, according to the mean estimate from 4 analysts, based on LSEG data.
LSEG's mean analyst estimate for Tenaya Therapeutics, Inc. is for a loss of 10 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts had fallen by about 0.5% in the last three months.
Wall Street's median 12-month price target for Tenaya Therapeutics, Inc. is $3.50, about 871.7% above its last closing price of $0.36
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Sep. 30 2026 | -0.10 | -0.10 | -0.08 | Beat | 22.6 |
Jun. 30 2026 | -0.06 | -0.07 | -0.20 | Missed | -192.7 |
Mar. 31 2026 | -0.08 | -0.09 | -0.09 | Met | -3.3 |
Dec. 31 2025 | -0.12 | -0.12 | -0.12 | Met | 1 |
Sep. 30 2025 | -0.14 | -0.15 | -0.12 | Beat | 18.8 |
Jun. 30 2025 | -0.25 | -0.25 | -0.14 | Beat | 44 |
Mar. 31 2025 | -0.19 | -0.19 | -0.24 | Missed | -26.3 |
Dec. 31 2024 | -0.31 | -0.28 | Beat | 10 |
This summary was machine generated November 7 at 00:56 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)